Alex Fotopoulos
Chief Tech/Sci/R&D Officer at PASSAGE BIO, INC.
Net worth: 106 236 $ as of 30/03/2024
Profile
Alex Fotopoulos is currently the Chief Technical Officer at Passage Bio, Inc. He previously worked as the Senior Director-Global Manufacturing Engineering at Biogen, Inc. from 1994 to 2011, Vice President-Technical Operations at Momenta Pharmaceuticals, Inc. from 2011 to 2016, Senior Vice President & Head-Technical Operations at Dimension Therapeutics, Inc. in 2016-2017, and Senior Vice President-Technical Operations at Ultragenyx Pharmaceutical, Inc. from 2017 to 2019.
Fotopoulos received a graduate degree from Tufts University in 1997 and an MBA from F.W.
Olin Graduate School of Business in 1998.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
PASSAGE BIO, INC.
0.14% | 17/03/2024 | 78,693 ( 0.14% ) | 106 236 $ | 30/03/2024 |
Alex Fotopoulos active positions
| Companies | Position | Start |
|---|---|---|
| PASSAGE BIO, INC. | Chief Tech/Sci/R&D Officer | 30/06/2019 |
Former positions of Alex Fotopoulos
| Companies | Position | End |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Chief Tech/Sci/R&D Officer | 30/06/2019 |
| DIMENSION THERAPEUTICS INC | Chief Tech/Sci/R&D Officer | 31/10/2017 |
| MOMENTA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 30/04/2016 |
| BIOGEN INC. | Corporate Officer/Principal | 31/12/2010 |
Training of Alex Fotopoulos
| Tufts University | Graduate Degree |
| F.W. Olin Graduate School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| BIOGEN INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| PASSAGE BIO, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Dimension Therapeutics, Inc.
 Dimension Therapeutics, Inc. BiotechnologyHealth Technology Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Alex Fotopoulos
